Immunohistochemical Detection of Somatostatin Receptor (SSTR) Subtypes 2A and 5 in Pituitary Adenoma from Acromegalic Patients: Good Correlation with Preoperative Response to Octreotide

Overview

Journal Endocr Pathol

Specialties Endocrinology
Pathology

Date 2007 Nov 8

PMID 17987403

Citations 15

Authors

Mao Takei

Masanori Suzuki

Hanako Kajiya

Yudo Ishii

Shigeyuki Tahara

Takashi Miyakoshi

Noboru Egashira

Susumu Takekoshi

Naoko Sanno

Akira Teramoto

Robert Yoshiyuki Osamura

Affiliations

Soon will be listed here.

Abstract

Objective: The aim of this study was to determine the correlation between the expression of somatostatin receptors by immunohistochemistry and the percent suppression of GH levels in the octreotide suppression test.

Patients And Methods: Twenty-two patients with acromegaly who underwent an octreotide suppression test before surgery were studied. We performed immunohistochemistry for Somatostatin receptor 2A (SSTR2A) and Somatostatin receptor 5 (SSTR5) on the surgical specimens from all patients, which we scored according to the number of tumor cells staining positive at the surface membrane (3+: >50%, 2+: 25-50%, 1+: <25%). We sought correlations of percent suppression in the octreotide suppression test with these immunohistochemistry scores.

Results: Somatostatin receptor 2A (SSTR2A) showed the highest frequency of score 3+ (13 of 22, 59.1%) by immunohistochemistry. Subtype 5 showed the highest frequency for score 2+ (9 of 22, 40.9%), and one (4.5%) was immunonegative. For subtype 2A, there was a significant correlation with percent decrease (P = 0.002 < 0.01). In contrast, there was no significant correlation for SSTR5.

Conclusion: Immunohistochemistry for SSTR2A in pathology specimens from acromegalic patients enabled selection of those experiencing clinical benefit from octreotide. Therefore, performing immunohistochemistry for detection of SSTR2A is recommended for all specimens obtained by surgery.

Citing Articles

Somatostatin receptors in pituitary somatotroph adenomas as predictors of response to somatostatin receptor ligands: A pathologist's perspective.

Botelho L, Dezonne R, Wildemberg L, Lyra Miranda R, Gadelha M, Andreiuolo F Brain Pathol. 2024; 35(1):e13313.

PMID: 39473262 PMC: 11669419. DOI: 10.1111/bpa.13313.

Drug resistance in pituitary tumours: from cell membrane to intracellular signalling.

Peverelli E, Treppiedi D, Mangili F, Catalano R, Spada A, Mantovani G Nat Rev Endocrinol. 2021; 17(9):560-571.

PMID: 34194011 DOI: 10.1038/s41574-021-00514-0.

Up-regulation of sex-determining region Y-box 9 (SOX9) in growth hormone-secreting pituitary adenomas.

Shirian F, Ghorbani M, Khamseh M, Imani M, Panahi M, Alimohammadi A BMC Endocr Disord. 2021; 21(1):50.

PMID: 33736633 PMC: 7971953. DOI: 10.1186/s12902-021-00720-x.

Clinical, biological, radiological, and pathological comparison of sparsely and densely granulated somatotroph adenomas: a single center experience from a cohort of 131 patients with acromegaly.

Swanson A, Erickson D, Donegan D, Jenkins S, Van Gompel J, Atkinson J Pituitary. 2020; 24(2):192-206.

PMID: 33074402 DOI: 10.1007/s11102-020-01096-2.

Follicle-stimulating Hormone-secreting Pituitary Adenoma Accompanied by Painful Thyroiditis.

Ichijo M, Tsuchiya K, Kasai T, Inoshita N, Yoshimoto H, Yamada S Intern Med. 2019; 59(4):545-550.

PMID: 31611532 PMC: 7056379. DOI: 10.2169/internalmedicine.3667-19.

References

Plockinger U, Reichel M, Fett U, Saeger W, Quabbe H . Preoperative octreotide treatment of growth hormone-secreting and clinically nonfunctioning pituitary macroadenomas: effect on tumor volume and lack of correlation with immunohistochemistry and somatostatin receptor scintigraphy. J Clin Endocrinol Metab. 1994; 79(5):1416-23. DOI: 10.1210/jcem.79.5.7962337. View

Lancranjan I, Atkinson A . Results of a European multicentre study with Sandostatin LAR in acromegalic patients. Sandostatin LAR Group. Pituitary. 2000; 1(2):105-14. DOI: 10.1023/a:1009980404404. View

Ahmed S, Elsheikh M, Stratton I, Page R, Adams C, Wass J . Outcome of transphenoidal surgery for acromegaly and its relationship to surgical experience. Clin Endocrinol (Oxf). 1999; 50(5):561-7. DOI: 10.1046/j.1365-2265.1999.00760.x. View

Cozzi R, Dallabonzana D, Attanasio R, Barausse M, Oppizzi G . A comparison between octreotide-LAR and lanreotide-SR in the chronic treatment of acromegaly. Eur J Endocrinol. 1999; 141(3):267-71. DOI: 10.1530/eje.0.1410267. View

Bengtsson B, Eden S, Ernest I, Oden A, Sjogren B . Epidemiology and long-term survival in acromegaly. A study of 166 cases diagnosed between 1955 and 1984. Acta Med Scand. 1988; 223(4):327-35. DOI: 10.1111/j.0954-6820.1988.tb15881.x. View

Biermasz N, Pereira A, Smit J, Romijn J, Roelfsema F . Intravenous octreotide test predicts the long term outcome of treatment with octreotide-long-acting repeatable in active acromegaly. Growth Horm IGF Res. 2005; 15(3):200-6. DOI: 10.1016/j.ghir.2005.02.007. View

de Herder W, Taal H, Uitterlinden P, Feelders R, Janssen J, van der Lely A . Limited predictive value of an acute test with subcutaneous octreotide for long-term IGF-I normalization with Sandostatin LAR in acromegaly. Eur J Endocrinol. 2005; 153(1):67-71. DOI: 10.1530/eje.1.01935. View

Shimon I, Melmed S . Structure and function of somatostatin receptors in growth hormone control. J Endocrinol. 1997; 155 Suppl 1:S3-6; discussion S7-8. View

Masuda A, Shibasaki T, Kim Y, Imaki T, Hotta M, Demura H . The somatostatin analog octreotide inhibits the secretion of growth hormone (GH)-releasing hormone, thyrotropin, and GH in man. J Clin Endocrinol Metab. 1989; 69(4):906-9. DOI: 10.1210/jcem-69-4-906. View

10.

Lindsay J, McConnell E, Hunter S, McCance D, Sheridan B, Atkinson A . Poor responses to a test dose of subcutaneous octreotide predict the need for adjuvant therapy to achieve 'safe' growth hormone levels. Pituitary. 2005; 7(3):139-144. DOI: 10.1007/s11102-005-1756-2. View

11.

Newman C, Melmed S, Snyder P, Young W, BOYAJY L, Levy R . Safety and efficacy of long-term octreotide therapy of acromegaly: results of a multicenter trial in 103 patients--a clinical research center study. J Clin Endocrinol Metab. 1995; 80(9):2768-75. DOI: 10.1210/jcem.80.9.7673422. View

12.

Saveanu A, Gunz G, Dufour H, Caron P, Fina F, Ouafik L . Bim-23244, a somatostatin receptor subtype 2- and 5-selective analog with enhanced efficacy in suppressing growth hormone (GH) from octreotide-resistant human GH-secreting adenomas. J Clin Endocrinol Metab. 2001; 86(1):140-5. DOI: 10.1210/jcem.86.1.7099. View

13.

Thodou E, Kontogeorgos G, Theodossiou D, Pateraki M . Mapping of somatostatin receptor types in GH or/and PRL producing pituitary adenomas. J Clin Pathol. 2006; 59(3):274-9. PMC: 1860351. DOI: 10.1136/jcp.2005.026914. View

14.

Reubi J, LANDOLT A . The growth hormone responses to octreotide in acromegaly correlate with adenoma somatostatin receptor status. J Clin Endocrinol Metab. 1989; 68(4):844-50. DOI: 10.1210/jcem-68-4-844. View

15.

Lamberts S, Uitterlinden P, Schuijff P, Klijn J . Therapy of acromegaly with sandostatin: the predictive value of an acute test, the value of serum somatomedin-C measurements in dose adjustment and the definition of a biochemical 'cure'. Clin Endocrinol (Oxf). 1988; 29(4):411-20. DOI: 10.1111/j.1365-2265.1988.tb02890.x. View

16.

Casarini A, Pinto E, Jallad R, Giorgi R, Giannella-Neto D, Bronstein M . Dissociation between tumor shrinkage and hormonal response during somatostatin analog treatment in an acromegalic patient: preferential expression of somatostatin receptor subtype 3. J Endocrinol Invest. 2006; 29(9):826-30. DOI: 10.1007/BF03347378. View

17.

Ayuk J, Stewart S, Stewart P, Sheppard M . Long-term safety and efficacy of depot long-acting somatostatin analogs for the treatment of acromegaly. J Clin Endocrinol Metab. 2002; 87(9):4142-6. DOI: 10.1210/jc.2001-011913. View

18.

Sassolas G, Harris A . Long term effect of incremental doses of the somatostatin analog SMS 201-995 in 58 acromegalic patients. French SMS 201-995 approximately equal to Acromegaly Study Group. J Clin Endocrinol Metab. 1990; 71(2):391-7. DOI: 10.1210/jcem-71-2-391. View

19.

Colao A, Ferone D, Marzullo P, Lombardi G . Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev. 2004; 25(1):102-52. DOI: 10.1210/er.2002-0022. View

20.

Biermasz N, van Dulken H, Roelfsema F . Long-term follow-up results of postoperative radiotherapy in 36 patients with acromegaly. J Clin Endocrinol Metab. 2000; 85(7):2476-82. DOI: 10.1210/jcem.85.7.6699. View